chronic lymphocytic leukemia

Research in Review
CLL Long-Term Survival Likely to Improve With Novel Therapies
07/26/2017
JCP Editors
Novel agents are predicted to significantly improve lifetime overall survival (OS) and quality-adjusted life-years (QALYs) compared with traditional therapies for patients with chronic lymphocytic leukemia (CLL),...
Novel agents are predicted to significantly improve lifetime overall survival (OS) and quality-adjusted life-years (QALYs) compared with traditional therapies for patients with chronic lymphocytic leukemia (CLL),...
Novel...
07/26/2017
Journal of Clinical Pathways
Research in Review
New Therapy Highly Effective in Treatment-Resistant CLL
07/18/2017
JCP Editors
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A...
07/18/2017
Journal of Clinical Pathways
Research in Review
CAR-T Therapy Highly Effective in Treatment-Resistant CLL
07/18/2017
JCP Editors
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A...
07/18/2017
Journal of Clinical Pathways
Research in Review
Targeted Therapy Improves Survival in Older Patients With B-Cell Malignancy
06/27/2017
JCP Editors
A targeting agent is more effective in improving progression-free survival (PFS) and overall survival (OS) than conventional therapy in older patients with a treatment-naïve B-cell malignancy, according to research...
A targeting agent is more effective in improving progression-free survival (PFS) and overall survival (OS) than conventional therapy in older patients with a treatment-naïve B-cell malignancy, according to research...
A...
06/27/2017
Journal of Clinical Pathways
Research in Review
Adding Targeted Therapy Improves CAR-T Response Rates in CLL
06/15/2017
JCP Editors
Researchers report significantly improved response rates in patients with chronic lymphocytic leukemia (CLL) treated with concurrent targeted therapy and chimeric antigen receptor T-cell (CAR-T)...
Researchers report significantly improved response rates in patients with chronic lymphocytic leukemia (CLL) treated with concurrent targeted therapy and chimeric antigen receptor T-cell (CAR-T)...
...
06/15/2017
Journal of Clinical Pathways
Research in Review
Mutations in CLL Cells May Be Used as Biomarker for Future Relapse
05/09/2017
JCP Editors
Certain mutations in relapsed chronic lymphocytic leukemia (CLL) after targeted therapy have the potential to be used as a biomarker for relapse, according to research published in the Journal of Clinical Oncology...
Certain mutations in relapsed chronic lymphocytic leukemia (CLL) after targeted therapy have the potential to be used as a biomarker for relapse, according to research published in the Journal of Clinical Oncology...
...
05/09/2017
Journal of Clinical Pathways
Research in Review
Older Patients With CLL Have Higher Risk of Disease-Related Mortality
05/04/2017
JCP Editors
Chronic lymphocytic leukemia (CLL)-related mortality is significantly higher in patients aged 75 years or older, prompting a need for novel treatment options, according to a study published in BMC Cancer...
Chronic lymphocytic leukemia (CLL)-related mortality is significantly higher in patients aged 75 years or older, prompting a need for novel treatment options, according to a study published in BMC Cancer...
...
05/04/2017
Journal of Clinical Pathways
Research in Review
Combination Therapy Improves Outcomes for Patients With CLL
03/10/2017
JCP Editors
The addition of a novel monoclonal antibody to ibrutinib significantly improves survival outcomes for patients with previously treated high-risk chronic lymphocytic leukemia (CLL), according to the results of a phase...
The addition of a novel monoclonal antibody to ibrutinib significantly improves survival outcomes for patients with previously treated high-risk chronic lymphocytic leukemia (CLL), according to the results of a phase...
The...
03/10/2017
Journal of Clinical Pathways
Research in Review
Consolidation Therapy With Chemo Improves Survival for Patients With CLL
03/06/2017
JCP Editors
An intravenous consolidation regimen developed for patients with chronic lymphocytic leukemia (CLL) was found to be safe and effective, according to a report in the European Journal of...
An intravenous consolidation regimen developed for patients with chronic lymphocytic leukemia (CLL) was found to be safe and effective, according to a report in the European Journal of...
An...
03/06/2017
Journal of Clinical Pathways
Research in Review
Genetic Mutations May Be Used as Biomarkers for Relapsing CLL
02/24/2017
JCP Editors
Mutations in the BTK and PLCG2 genes have the potential to be used as a biomarker for relapse of chronic lymphocytic leukemia (CLL) after treatment with ibrutinib, according to a retrospective review published in the...
Mutations in the BTK and PLCG2 genes have the potential to be used as a biomarker for relapse of chronic lymphocytic leukemia (CLL) after treatment with ibrutinib, according to a retrospective review published in the...
...
02/24/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use